eli lilly tirzepatide direct to consumer releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity A major shift is unfolding

Hammarlund, M., Hobert, O., Miller, D

Tirzepatide trials often show greater average weight loss, but both medications reduce appetite and improve metabolic markers when paired with diet and activity

"FRAGMENT 176- 191- 5MG SKU PN-FR-001 Rating: 99% of 100

In December 2023, Eli Lilly and Company, one of the major GLP-1 receptor agonist companies, announced the availability of Zepbound (tirzepatide) injection, a GLP-1 drug, in the U.S

Regular intake can help reduce joint pain, stiffness, and inflammation, making movement smoother

From supporting digestion to reducing the risk of dehydration-related complications, water is part of the treatment plan